Background Positron emission tomography/computed tomography (PET/CT) fails to detect approximately 25% of aortic lymph node metastasis in patients with PET/CT stage IIIC1 cervical cancer. Surgical staging could lead to treatment modification and to improved para-aortic and distant control.
Primary Objective(s) To demonstrate if chemoradiation with tailored external beam radiation field based on surgical staging and pathologic examination of the para-aortic lymph node is associated with improved 3-year disease-free survival compared with patients staged with PET/CT staging only.
Study Hypothesis Surgical staging followed by tailored chemoradiation will improve disease-free survival while avoiding unnecessary prophylactic extended-field chemoradiation in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC1 cervical cancer.
Trial Design This is an international multicenter, randomized, phase III study. Eligible patients will be randomized 1:1 between PET/CT staging followed by chemoradiation (control arm), or surgical staging followed by tailored chemo-radiation (experimental arm). Randomization will be stratified by tumor stage according to TNM classification, center, and adjuvant treatment.
Major Inclusion/Exclusion Criteria Main inclusion criteria are histologically proven PET/CT FIGO stage IIIC1 cervical cancer. Main exclusion criteria include unequivocal positive common iliac or para-aortic lymph node at pre-therapeutic imaging PET/CT.
Primary Endpoint(s) The primary endpoint is disease-free survival defined as the time from randomization until first relapse (local, regional, or distant), or death from any cause.
Sample Size 510 eligible patients
Estimated Dates for Completing Accrual and Presenting Results The estimated date for completing accrual will be Q2 2027. The estimated date for presenting results will be Q4 2030.
Trial Registration Number NCT05581121.
- cervical cancer
- lymph nodes
- radiotherapy, intensity-modulated
Data availability statement
No data are available.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @Alejandra, @annafagottimd, @frafanfani, @Bertadiazfeijoo#, @AngelesFite, @ZMuallem, @pedroramirezMD, @frumovitz
Collaborators PAROLA Study Group: Stéphanie Motton, Elodie Chantalat, Yann Tanguy le Gac, Enora Laas, Fabrice Narducci, Eric Lambaudie, Sebastien Gouy, Charles André Philip, Catherine Uzan, Cyril Touboul, Cyrille Huchon, C Durdux, Frédéric Guyon, Agathe Crouzet, Hélène Costaz, Bruno Borghese, Pierre-Emmanuel Colombo, Nicolas Chopin, Cherif Akladios, Marcos Ballester, Catherine Ferrer.
Contributors All authors made the appropriate contributions, carefully compiling and analyzing data, reading the manuscript and giving their full approval. AM accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.
Funding This study was funded by French National Cancer Institute (Grant number: PHRC-22-161).
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.